Comparison of Effectiveness and Safety of Antiarrhythmic Drugs Class IC and III in Patients After Electrical Cardioversion

Arnold, A. Z., Mick, M. J., Mazurek, R. P., Loop, F. D., Trohman, R. G. (1992). Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J. Amer. Coll. Cardiol., 19, 851–855.10.1016/0735-1097(92)90530-ZSearch in Google Scholar

Camm, A. J., Savelieva, I. (2014) Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin. Cardiol., 37 (1), 32–47.10.1002/clc.22204Search in Google Scholar

Cannon, C. P., Armani, A. M. (2008). Atrial Fibrillation – From Bench to Bedside. Humana Press. 46 pp.Search in Google Scholar

Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y. H., McAnulty, J. H. Jr., Zheng, Z. J., Forouzanfar, M. H., Naghavi, M., Mensah, G. A., Ezzati, M., Murray, C. J. (2014). Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation, 129, 837–847.10.1161/CIRCULATIONAHA.113.005119415130224345399Search in Google Scholar

Femia, G., Fetahovic, T., Shetty, P., Lee, A. (2017). Novel oral anticoagulants in direct current cardioversion for atrial fibrillation. Heart Lung Circ., 27 (7), 798–803.10.1016/j.hlc.2017.06.726Search in Google Scholar

Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J, Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., Heit, J. A., Howard, V. J., Huffman, M. D., Judd, S. E., Kissela, B. M., Kittner, S. J., Lackland, D. T., Lichtman, J. H., Lisabeth, L. D., Mackey, R. H., Magid, D. J., Marcus, G. M., Marelli, A., Matchar, D. B., McGuire, D. K., Mohler, E. R. 3rd., Moy, C. S., Mussolino, M. E., Neumar, R. W., Nichol, G., Pandey, D. K., Paynter, N. P., Reeves, M. J., Sorlie, P. D., Stein, J., Towfighi, A., Turan, T. N., Virani, S. S., Wong, N. D., Woo, D., Turner, M. B. (2014). American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 129, e28–e292.10.1161/01.cir.0000441139.02102.80Search in Google Scholar

Hart, R. G., Pearce, L. A., Aguilar, M. I. (2007). Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.,146, 857–867.10.7326/0003-4819-146-12-200706190-0000717577005Search in Google Scholar

Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H. C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P. (2017). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Eur. Heart J., 38 (27), 2137–2149.10.1093/eurheartj/ehw058Search in Google Scholar

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellá, M., Diener, H. C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Alexandru, P. B., Schotten, U., Van P. B., Vardas, P. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 37, 2893–2962.10.1093/eurheartj/ehw21027567408Search in Google Scholar

Kirchhof, P., Monnig, G., Wasmer, K., Heinecke, A., Breithardt, G., Eckardt, L., Bocker, D. (2005) A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur. Heart J., 26, 1292–1297.10.1093/eurheartj/ehi160Search in Google Scholar

Lloyd-Jones, D. M.,Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D’Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., Benjamin, E. J. (2004). Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation, 110, 1042–1046.10.1161/01.CIR.0000140263.20897.4215313941Search in Google Scholar

Nuotio, I., Hartikainen, J. E., Grönberg, T., Biancari, F., Airaksinen, K. E. (2014). Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA,312, 647–649.10.1001/jama.2014.382425117135Search in Google Scholar

Olesen, J. B., Sørensen, R., Hansen, M. L., Lamberts, M., Weeke, P., Mikkelsen, A. P., Køber, L., Gislason, G. H., Torp-Pedersen, C., Fosbøl, E. L. (2015). Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace, 17 (2), 187–193.10.1093/europace/euu22525236181Search in Google Scholar

Ott, A., Breteler, M. M., de Bruyne, M. C., van Harskamp, F., Grobbee, D. E., Hofman, A. (1997). Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke, 28, 316–321.10.1161/01.STR.28.2.3169040682Search in Google Scholar

Pisters, R., Nieuwlaat, R., Prins, M. H., Le Heuzey, J. Y., Aldo, P., Maggioni, A., Camm, A. J., Crijns, H. J. (2012). Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: The Euro Heart Survey. Europace, 5 (14), 666–674.10.1093/europace/eur40622223715Search in Google Scholar

Pupkevica, I., Lituņenko, O., Vīnkalna, I., Strēlnieks, A., Šime, I., Stirna, V., Kovaļova, M., Rancāne, R., Miglāne, E., Tilgale, B., Trušinskis, K., Kalējs, O., Lejnieks, A. (2014). Risk of cardiovascular events in patients with atrial fibrillation after electrical cardioversion. RSU Scientific Articles,4,122–137.Search in Google Scholar

Singh, S. N., Tang, X. C., Reda, D., Singh, B. N. (2009). Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: A substudy of the SAFE-T trial. Heart Rhythm, 6 (2), 152–155.10.1016/j.hrthm.2008.10.03619187902Search in Google Scholar

Stampfuss, J., Kubitza, D., Becka, M., Mueck, W. (2013). The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int. J. Clin. Pharmacol. Ther., 51 (7), 549–561.10.5414/CP201812Search in Google Scholar

Stewart, S., Murphy, N., Walker, A., McGuire, A., McMurray, J. J. V. (2004). Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart, 90, 286–29210.1136/hrt.2002.008748Search in Google Scholar

Strēlnieks, A., Vīnkalna, I., Lituņenko, O., Pupkevica, I., Šime, I., Vikmane, M., Kovaļova, M., Rancāne, M., Dormidontova, G., Sakne, S., Pudulis, J., Mintāle, I., Kalējs, O., Lejnieks, A. (2014). Atrial fibrillation and risk factors of recurrent paroxysms after electrical cardioversion. RSU Scientific Articles,4, 137–157.Search in Google Scholar

Sucu, M., Davutoglu, V., Ozer, O. (2009). Electrical cardioversion. Annu. Saudi Med., 29 (3), 201–206.10.5144/0256-4947.51775Search in Google Scholar

Weinberg, D. M., Mancini, J. (1989). Anticoagulation for cardioversion of atrial fibrillation. Amer. J. Cardiol., 63, 745–746.10.1016/0002-9149(89)90264-6Search in Google Scholar

Wolf, P. A., Abbott, R. D., Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke, 22, 983–988.10.1161/01.STR.22.8.9831866765Search in Google Scholar

Xiong, Q., Proietti, M., Senoo, K., Lip, G. Y. (2015). Asymptomatic versus symptomatic atrial fibrillation: A systematicreview of age/gender differences and cardiovascular outcomes. Int. J. Cardiol., 191, 172–177.10.1016/j.ijcard.2015.05.01125974193Search in Google Scholar